SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovins stronger-than-expected quarterly results, upbeat forward guidance, and expanded share-repurchase authorization are driving a sharp rally. Bulls see the report as a sign that growth remains intact and a possible squeeze on short sellers, while others warn the earnings-fueled move could fade and are taking profits.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snaps quarterly results are driving attention, with softer ad growth and weaker North American daily-user trends weighing on sentiment despite improved profitability and cash generation. Traders are split between focusing on the user and advertising concerns and seeing progress in subscriptions and operating efficiency as evidence of a turnaround.

Redwire Corp. engages in the development and provision of space and defense technologies and mission-critical solutions for government, commercial, and civil customers. Its offerings include spacecraft platforms, space infrastructure, avionics, sensors and payloads, power generation systems, radio frequency systems, microgravity research and manufacturing technologies, autonomous systems, optical sensors, and digital engineering solutions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwires quarterly results are driving discussion, with traders weighing weaker-than-expected revenue and an underwhelming outlook against improved margins, a record backlog, and reaffirmed guidance. The share-price drop has prompted debate over execution and possible further dilution, while some investors see the operational progress as encouraging.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomms agreement to supply chips and software for SpaceXs planned Starlink Mobile network is drawing attention, with traders debating its long-term potential against questions about execution and timing. The conversation also centers on mixed earnings: a modest beat and growth in automotive were weighed against handset weakness, cost pressures and cautious guidance.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arms quarterly results beat expectations, but shares sold off as traders judged the outlook roughly in line and questioned whether it justified the stocks valuation. Bulls point to AI and data-center demand and see a buying opportunity, while bears cite high expectations and weakness across semiconductor stocks.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros shares sold off sharply around its Q3 report despite a narrow earnings beat, with traders focused on concerns about slowing growth, elevated costs and the stocks rich valuation. Bears also point to pricey drinks, consumer pressure and competition from 7 Brew, while bulls argue the decline is overdone and view the pullback as a buying opportunity.

Coherent Corp. engages in the development, refinement, manufacturing, and marketing of engineered materials, opto-electronic components and devices, and lasers for use in the industrial, communications, electronics, and instrumentation markets. It operates through the following segments: Networking, Materials, and Lasers. The Networking segment leverages compound semiconductor technology platforms and deep knowledge of end-user applications. The Materials segment markets engineered materials and optoelectronic devices. The Lasers segment serves industrial customers in semiconductor capital equipment, display capital equipment, precision manufacturing, and aerospace and defense, as well as instrumentation customers in life sciences and scientific research. The company was founded by Carl J. Johnson in 1971 and is headquartered in Saxonburg, PA.

Coherent Corp

Coherents strong earnings, raised outlook, and reported multiyear customer agreement for AI data-center optics are drawing attention. Traders are split between viewing the results as evidence of durable demand and seeing the share decline as part of a broader AI-sector selloff, with some questioning whether growth expectations are already priced in.

Joby Aviation, Inc. is a transportation company, which engages in developing an all-electric, vertical take-off and landing aircraft that intends to operate as a commercial passenger aircraft. The company was founded by Bevirt Joebenn in 2009 and is headquartered in Santa Cruz, CA.

Joby Aviation Inc

JOBYs steep selloff and new lows have fueled debate over a bearish Barclays downgrade, cash burn and uncertainty about the pace of FAA certification. Bulls point to certification progress, Toyotas backing and defense opportunities, while bears argue commercialization remains distant and further funding may be needed.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IRENs selloff is being discussed amid fears that election-driven policy shifts could slow Texas data-center development, alongside reports of Microsoft spending cuts and delays tied to IREN projects as earnings approach. Bears focus on regulatory and execution risks, while bulls argue that IRENs existing sites and power could become more valuable if new construction faces hurdles; the reported delays remain disputed.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

TTD is drawing attention around earnings, as traders question whether advertising growth and guidance can reverse the stocks prolonged decline amid concerns about competition and execution. Bears expect further weakness and criticize management, while bulls point to heavy short interest and oversold conditions as possible support for a rebound.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Big Money, Bold Science, and Next Wave of Biotech Catalysts

Biotechnology is delivering a fresh wave of developments that could reshape investor expectations for Disc Medicine (NASDAQ:IRON), Silence Therapeutics (NASDAQ:SLN), NeOnc Technologies Holdings (NASDAQ:NTHI), and Alaunos Therapeutics (NASDAQ:TCRT).

High-Stakes Corporate Stories Putting Strategic Moves in the Spotlight

Today's corporate developments highlight some very different investment narratives: NeOnc Technologies Holdings (NASDAQ:NTHI) is pursuing new avenues for experimental brain-cancer treatments, Alector (NASDAQ:ALEC) is raising fresh capital for neurological disease research, Alaunos Therapeutics (NASDAQ:TCRT) is repositioning around pulmonary hypertension through a major acquisition, Zenta Group (NASDAQ:ZTG) is pursuing an artificial intelligence and data-services strategy, and Exascale Labs (NASDAQ:XLAB) is seeking to convert surging AI-computing demand into commercial growth.

Alaunos’ $350 Million Velaris Deal Targets New Frontier in Pulmonary Hypertension

Alaunos Therapeutics (NASDAQ:TCRT) completed its acquisition of Velaris Therapeutics and secured approximately $350 million in gross private-placement proceeds, setting up an aggressive push into pulmonary arterial hypertension (PAH) with a clinical pipeline targeting multiple disease-driving pathways.

12 Health Care Stocks Moving In Thursday's After-Market Session

Gainers

Alaunos Therapeutics (NASDAQ:TCRT) stock rose 34.9% to $2.94 during Thursday's after-market session. The market value of their outstanding shares is at $7.6 million.
Senti Biosciences (NASDAQ:SNTI) stockread more...

Wall Street’s Next Movers

The market is serving up a powerful mix of movers, including Alaunos Therapeutics (NASDAQ:TCRT) completed a major acquisition backed by a $350 million private placement, while NeOnc Technologies Holdings (NASDAQ:NTHI) is preparing for an important FDA discussion. Verastem Oncology (NASDAQ:VSTM) reported fresh cancer-drug results alongside a major financing and leadership transition, and Liquidia (NASDAQ:LQDA) resolved a prolonged legal battle over its pulmonary-hypertension treatment. Bending Spoons (NASDAQ:BSP) is attracting another major investment from Berkshire Hathaway.

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers

Alaunos Therapeutics (NASDAQ:TCRT) shares rose 20.5% to $3.65 during Tuesday's after-market session. The market value of their outstanding shares is at $2.6 million.
Circle8 Group (NASDAQ:CIRC) stock movedread more...

Why is Alaunos Therapeutics Stock Trading 200% Higher on Tuesday?

Alaunos Therapeutics acquired Velaris and raised $350 million to advance clinical therapies for pulmonary arterial hypertension through 2029.read more...

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gainers

Alaunos Therapeutics (NASDAQ:TCRT) stock moved upwards by 203.8% to $3.19 during Tuesday's regular session. The company's market cap stands at $2.6 million.
Picard Medical (AMEX:PMI) stock movedread more...

Market Moves Investors Can’t Ignore

Five companies, six developing stories, including Totaligent (OTCID:TGNT), Fermi America (NASDAQ:FRMI), Advanced Micro Devices (NASDAQ:AMD), Alaunos Therapeutics (NASDAQ:TCRT), BIO-key International (NASDAQ:BKYI), and Bumble (NASDAQ:BMBL).

Paragon Recruits Apogee’s Former Leaders After $10.9 Billion AbbVie Buyout

Alaunos Therapeutics (NASDAQ:TCRT) has completed its acquisition of Velaris Therapeutics, a privately held biotech developing treatments for pulmonary arterial hypertension (PAH) and related cardiopulmonary diseases. Velaris is the ninth company built around assets discovered by Paragon and the first launched with support from Paragon’s expanded leadership team.

Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Fort Lauderdale, FL.

Alaunos Therapeutics Inc

Alaunos Reports Positive Preclinical Obesity Drug Results Across Weight, Liver, Insulin Markers

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Researchers observed treatment-linked improvements in body composition, including lower fat mass and relatively higher lean mass.</li><li>The drug candidate was associated with lower fasting insulin, better insulin resistance readings and signs of reduced fatty liver activity.</li><li>Alaunos said it is optimizing the drug’s formulation after some dose-related reductions in water intake affected part of the study data.</li></ul><p>Alaunos Therapeutics (TCRT) shared new preclinical data for ALN1003, its experimental obesity drug candidate, on Tuesday. The oral treatment is being developed for obesity and related metabolic disorders without using hormones or incretin-based mechanisms.</p><p>The TCRT stock was, however, down 1.66% at the time of writing.&nbsp;</p><h2 class="st-heading-2">Study Combined Findings From Multiple Obesity Trials</h2><p>The company combined data from two earlier non-Good Laboratory Practice (non-GLP) diet-induced obesity (DIO) mouse studies reported on March 2 and May 18, along with new cross-study analyses released in a presentation published on Tuesday. The studies looked at how ALN1003 affected several key markers linked to obesity and metabolic disorders.</p><p>According to the company, the treatment was associated with lower body weight and reduced food intake. Researchers also observed lower fat mass and relatively higher lean mass levels in treated mice.&nbsp;</p><h2 class="st-heading-2">Improvements Across Metabolic Health Markers</h2><p>The data also pointed to improvements in insulin resistance and liver-related markers. Alaunos said treated mice showed lower fasting insulin levels and better HOMA-IR readings, which are commonly used to measure insulin resistance.</p><p>Researchers also reported signs of improved liver health. This included “lower liver weight, lower liver-injury and cholestatic enzymes and qualitative liver histology findings consistent with lower hepatic steatosis,” the company said.</p><p>Alaunos added that metabolic syndrome affects multiple organ systems in the body, and believes “a profile that engages several of these systems may be important for future therapeutic approaches.”&nbsp;</p><h2 class="st-heading-2">Mouse Studies Showed Weight, Metabolic, Liver Improvements</h2><p>Alaunos said the two DIO mouse studies evaluating ALN1003 showed improvements across many obesity and metabolic health markers. In the longer 48-day study, the drug was linked to lower body weight, improved insulin resistance markers, healthier fat-related hormone signaling and signs of better liver health.</p><p>In the shorter 18-day study, researchers tested multiple dose levels and observed changes in body weight, fat loss, glucose, cholesterol and liver weight.</p><h2 class="st-heading-2">TCRT Stock: What Does Retail Think?</h2><p>Despite the study results, retail sentiment on Stocktwits turned “bearish” from “neutral” a day ago.&nbsp;</p><p>Year-to-date, the&nbsp;<a href="https://stocktwits.com/symbol/TCRT">TCRT stock</a> has fallen nearly 28%.</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Azitra Inc, a micro-cap dermatology company, was among the top trending stocks on Stocktwits on Wednesday.

Alaunos Therapeutics (TCRT) shared new preclinical data for ALN1003, its experimental obesity drug candidate. 

Alaunos Therapeutics Reports Encouraging Early Obesity Drug Results

Preclinical findings for obesity drug candidate ALN1003 showed metabolic improvements, adding to interest in next-generation treatments beyond GLP-1 drugs.

Current Price	$1.80
Prev Close	$1.86
Open	$1.82
Dividend Yield	0.00%
50-Day Moving Average	$1.64
Beta	0.94
Avg. Volume	19.64M
PE Ratio	-0.95

52-Week High	$4.50
52-Week Low	$0.719
Market Capitalization	$7.68M
EPS (Annual)	-$2.20
Price to Book	7.09
Revenue Per Employee	$5,000.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

TCRT Fundamentals